KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $13.7 million.

  • Xenon Pharmaceuticals' Share-based Compensation rose 540.69% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 1488.34%. This contributed to the annual value of $50.7 million for FY2024, which is 5666.93% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Share-based Compensation is $13.7 million, which was up 540.69% from $13.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Share-based Compensation high stood at $14.7 million for Q2 2024, and its period low was $2.0 million during Q1 2021.
  • For the 5-year period, Xenon Pharmaceuticals' Share-based Compensation averaged around $8.1 million, with its median value being $8.5 million (2023).
  • In the last 5 years, Xenon Pharmaceuticals' Share-based Compensation soared by 11725.31% in 2022 and then plummeted by 681.57% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Share-based Compensation (Quarter) stood at $2.7 million in 2021, then surged by 114.86% to $5.8 million in 2022, then skyrocketed by 57.98% to $9.2 million in 2023, then surged by 48.1% to $13.6 million in 2024, then rose by 0.78% to $13.7 million in 2025.
  • Its Share-based Compensation stands at $13.7 million for Q3 2025, versus $13.7 million for Q2 2025 and $12.2 million for Q1 2025.